课题基金 / 基金详情

项目摘要

项目成果

RICHARD A SLAYDEN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The goal of the Genomics Proteomics Core (Core E) of the Rocky Mountain Regional Center of Excellence in Biodefense (RMRCE) is to provide post-genomic resources and materials, to provide access to state-ofthe- art post-genomic instrumentation, and to provide expert assistance in performing post-genomic experiments, and bioinformatics, resulting in enhanced research opportunities for investigators at reduced costs. The GP-Core accomplishes this goal by producing whole genome mouse and pathogen DMA arrays and other molecular detection tools and platforms, by providing and maintaining post-genomic instrumentation in a centralized facility adjacent to the BL-3 laboratories, and by performing experimentation for investigators who would otherwise not be able to perform experiments because of a lack of manpower or expertise, and providing access to bioinformatics resources, staff, and support. The GP-Core also develops technology and custom platforms for investigators for focused or more advanced post-genomic studies. Accordingly, the GP-Core (1) produces and develops post-genomic resources for investigators, (2) provides access to post-genomic equipment (3) provides genomics, proteomics, and bioinformatics assistance and technical expertise, and (4) provides bioinformatics and Computer-Aided Drug Design (CADD) services to advance diagnostic and therapeutic drug discovery, design, and development for RMRCE investigators. Together, the activities of the GP-Core support research objectives on infectious diseases important to public health by providing resources and equipment that are required for post-genomic studies, technical assistance for experimental design, data analysis and other bioinformatics-related analyses, and postgenomic services on a fee-for-services basis. Core E will support all three of the RMRCE Integrated Research Foci on Immunomodulation, Adjuvants and Vaccines (IRF 1), Bacterial Therapeutics (IRF 2), and Viral Therapeutics (IRF 3). Its resources will be utilized by RPs 1.4, 1.6, 1.7, 2.1, 2.2, 2.3, 2.4, 2.5, 2.7 and 3.4
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of novel broad spectrum chemotherapeutics against priority pathogens
  • 批准号:
    8261425
  • 项目类别:
  • 资助金额:
    $34.07万
  • 财政年份:
    2011
  • 负责人:
    RICHARD A SLAYDEN
  • 依托单位:
Development and Formulation of Broad Spectrum Antimicrobials for Biodefense
  • 批准号:
    7932903
  • 项目类别:
  • 资助金额:
    $97.89万
  • 财政年份:
    2009
  • 负责人:
    RICHARD A SLAYDEN
  • 依托单位:
Development and Formulation of Broad Spectrum Antimicrobials for Biodefense
  • 批准号:
    7645264
  • 项目类别:
  • 资助金额:
    $97.92万
  • 财政年份:
    2009
  • 负责人:
    RICHARD A SLAYDEN
  • 依托单位:
Genomics Proteomics Core
  • 批准号:
    7675680
  • 项目类别:
  • 资助金额:
    $19.1万
  • 财政年份:
    2009
  • 负责人:
    RICHARD A SLAYDEN
  • 依托单位:
国内基金
海外基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    32170319
  • 项目类别:
    面上项目
  • 资助金额:
    58.00万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    --
  • 项目类别:
    --
  • 资助金额:
    58万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
  • 批准号:
    31372080
  • 项目类别:
    面上项目
  • 资助金额:
    80.0万元
  • 批准年份:
    2013
  • 负责人:
    杨迎伍
  • 依托单位: